Compare Amgen, Inc. (AMGN) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Schwab US Dividend Equity ETF — how do they compare? Amgen, Inc. trades at $413.01 (market cap $225.71B), while Schwab US Dividend Equity ETF trades at $34.25. The key difference: Amgen, Inc. pays a 2.42% dividend while Schwab US Dividend Equity ETF pays none. Which is the better fit depends on your goals.
| AMGN | SCHD | |
|---|---|---|
Market Cap | $225.71B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $417.20 | $34.27 |
52-Week Low | $271.18 | $26.44 |
Enterprise Value | $269.02B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $410.95, up 1.51% today, near its pivot point of $408. The stock shows bullish momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $6.29 versus $5.62 expected. Revenue reached $36.75B in 2025, with a net income margin of 22.95%. Analyst consensus is bullish with a 58.98% buy rating, though the current price exceeds the consensus target of $394.69. Technical indicators signal an overbought condition with RSI above 75.
Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high valuation multiples, significant debt levels, and competitive pressures. The stock's proximity to resistance at $415 suggests near-term consolidation may occur, yet fundamental strength supports long-term upside potential for investors focused on biotech growth.
SCHD, the Schwab U.S. Dividend Equity ETF, trades at $33.90, up 0.59% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on high-quality U.S. dividend-paying stocks, offering income stability. Recent news highlights its popularity among retirees for generating passive income, with institutional buying activity noted in Q2 2026 filings.
The outlook for SCHD remains positive for income-focused investors, leveraging dividend growth and low costs. Risks include interest rate sensitivity and market volatility affecting dividend stocks. Analyst sentiment is generally favorable, emphasizing its role in diversified retirement portfolios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
